Cancer-selective frameshifting circuits show preclinical activity with systemic AAV9 delivery
Academic source · Nature
Source published: · Event / reporting date: 2026-11-04
Site published: 2026-11-06 · Updated: 2026-11-06
This source is linked automatically. Choose a question to get started.
What the paper reports
A Nature study describes FAST gene circuits that exploit cancer-associated ribosomal frameshifting to conditionally express gasdermin D and trigger pyroptosis. According to the original abstract, systemic AAV9 delivery produced tumor regression and immune activation in mouse colorectal and pancreatic cancer models, with synergy alongside checkpoint blockade. These are cell and animal findings, not human clinical evidence.
Why this paper is included
Analysis: Translation-sensitive circuits may offer another selectivity layer for in vivo engineering, subject to delivery, off-target expression, and safety validation.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections